ABILIFY MAINTENA 960 mg, suspension for injection with extended release in a pre-filled syringe syringe, 3.2 ml + 2 needles
Active ingredients: Aripiprazole
Commercialized according to BDPMDispensing in France: Prescription only
Suspension for injection with extended releasesyringe, 3.2 ml + 2 needlesintramusculaire
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- ABILIFY MAINTENA 960 mg, suspension injectable à libération prolongée en seringue préremplie
- Pharmaceutical form
- suspension injectable à libération prolongée
- Route of administration
- intramusculaire
- Presentation description
- 1 seringue préremplie copolymère de cyclooléfines (COC) de 3,2 mL + 2 aiguilles sécurisées
- Marketing authorisation holder
- OTSUKA PHARMACEUTICAL NETHERLANDS (PAYS BAS)
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 5 Feb 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67269958CIP73028972CIP133400930289723Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| ARIPIPRAZOLEsuspension | 960 mg · une seringue préremplie de 3,2 mL | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.